Business Wire

Asus Selects OT-Morpho’s eSIM for the First Microsoft Windows 10 Tablet Computer Compliant with GSMA Specifications

Del

OT-Morpho, a world leader in digital security and identification technologies, today announced that ASUS has selected its embedded SIM (eSIM) to enable cellular connectivity for the new ASUS Transformer Mini, a hybrid tablet computer running with Windows 10 that will be launched this summer. The ASUS Transformer Mini will be the first computer device available on the market with an eSIM solution compatible with GSMA Phase 2 specifications for consumer devices.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170629005712/en/

ASUS selects OT-Morpho’s eSIM for the first Microsoft Windows 10 tablet computer compliant with GSMA ...

ASUS selects OT-Morpho’s eSIM for the first Microsoft Windows 10 tablet computer compliant with GSMA specifications (Photo: Oberthur Technologies)

DakOTa 4.0 eSIM contributes to enhance the Always Connected Windows user experience. It has been designed in compliance with the GSMA specifications to ensure the best compatibility with MNO networks worldwide and thus allow the largest coverage capabilities. It fully addresses the specific subscription management needs for consumer devices. Validated for Microsoft Windows 10, it enables device makers such as ASUS to offer greater connectivity capabilities for laptops, notebooks and other personal computer devices using Windows OS.

To stay connected anywhere, users will no longer need to buy various SIM cards when travelling. The eSIM will enable ASUS Transformer Mini owners to download the subscription they need by selecting one of the available cellular networks directly from their device. Furthermore, thanks to the initial cellular connectivity embedded in their device, they will be able to connect to the Microsoft Data Market place to select the subscription of their choice wherever they are, even if they do not have access to WiFi.

“We position ourselves as a champion of connectivity in the personal computer space and we are excited to provide our customers with access to cellular connectivity anytime, anywhere,” said S.Y. Shian, COO & Head of PC Business Unit at ASUS.

“We are very pleased to take part to the first GSMA Phase 2 eSIM deployment in personal computers with ASUS. Our close collaboration with Microsoft, notably with the two test labs we recently opened in the US and in Asia, allows us to offer the best-in-class support to our OEM customers for the integration of the eSIM technology to tablets, laptops and notebooks,” added Yves Portalier, OT-Morpho, Vice President & General Manager, Telecom, Morpho.

“Together with OT-Morpho, we anticipate the tremendous potential that eSIM technology has to transform connectivity usage in the personal computer space and we are working hand-in-hand to facilitate its deployment with the Windows 10 platform. We are very pleased to support ASUS in delivering extended cellular connectivity capabilities to their customers,” said Roanne Sones, General Manager, Strategy and Ecosystem for Windows and Devices at Microsoft.

Visitors to the MWC Shanghai (28-30 June 2017) will have the opportunity to discover the eSIM subscription management solution (stand W4.G01).

------

OT-Morpho is a world leader in digital security & identification technologies with the ambition to empower citizens and consumers alike to interact, pay, connect, commute, travel and even vote in ways that are now possible in a connected world.

As our physical and digital, civil and commercial lifestyles converge, OT-Morpho stands precisely at that crossroads to leverage the best in security and identity technologies and offer customized solutions to a wide range of international clients from key industries, including Financial services, Telecom, Identity, Security and IoT.

With close to €3bn in revenues and more than 14,000 employees, OT-Morpho is the result of the merger between OT (Oberthur Technologies) and Safran Identity & Security (Morpho) completed on 31 May 2017. Temporarily designated by the name

"OT-Morpho", the new company will unveil its new name in September of this year.

Contact information

OT-Morpho
Julien TAHMISSIAN, +33(0)158479054
julien.tahmissian@havas.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases18.11.2017 23:00Pressemelding

AstraZeneca today presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Results presented at the ESMO Asia 2017 Congress in Singapore showed that patients with central nervous system (CNS) metastases at baseline had a higher objective response rate with their brain metastasis and suggest a lower risk of CNS progression when treated with osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), versus current standard-of-care EGFR-TKIs (erlotinib or gefitinib) [Abstract LBA5].1 The analysis included patients with ≥1 measurable and/or non-measurable CNS lesion present on baseline scan (as assessed by blinded independent central review), accounting for 23

New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer18.11.2017 18:20Pressemelding

AstraZeneca today announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).1 The trial showed a statistically significant, clinically meaningful progression-free survival (PFS) advantage for osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI), compared with current 1st-line EGFR-TKIs, erlotinib or gefitinib.1 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171118005044/en/ Dr. Suresh S. Ramalingam, Principal Investigator of the FLAURA trial, from the Winship Cancer Institute

Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled18.11.2017 09:11Pressemelding

The 19th China Hi-Tech Fair (CHTF 2017), with the theme of “Innovation-Driven Development and Supply Quality Upgrade”, is taking place from November 16 to 21 at Shenzhen Convention and Exhibition Center. On the afternoon of November 10, the CHTF 2017 Top 10 Products were unveiled at the awards ceremony by Mr. Gao Zimin, Vice Mayor of Shenzhen City. A total of 322 entries competed for the honor Top 10 Products, and the voting lasted nearly 3 months. 60 candidate products in the fields of new energy, 3D print, flexible display, life sciences, unmanned vehicles and AI were shortlisted by the organizer, experts and media representatives and went for open voting online. The final Top 10 Products all represent the most advanced technologies in their respective sectors: the water-making device that can make water out of air, the smart sportswear that can monitor heartbeat and other

Madison Realty Capital Provides $64.0 Million Construction Financing for 200 Kent Avenue Development in Williamsburg, Brooklyn17.11.2017 16:20Pressemelding

Madison Realty Capital (MRC) announced the closing of a $64.0 million construction loan for 200 Kent Avenue, a 117,326 square foot mixed-use development located in Williamsburg, Brooklyn. The retail portion of the property, which will include over 600 feet of frontage, will be anchored by a popular national grocery chain. Overall, the project will offer 50,101 square feet of retail space, 22,055 square feet of office and restaurant space, and 45,170 square feet of parking. “We continue to establish MRC as the one-stop shop for financing transitional real estate, including ground-up development deals like 200 Kent Avenue,” said Josh Zegen, Co-Founder and Managing Principal of MRC. “In this case, we’re working with a repeat MRC borrower who understands our ability to execute efficiently, given our firm’s up-to-the minute knowledge of local market conditions and non-bureaucratic approach to

Ncardia Announces Completion of €10.5M Investment Round17.11.2017 12:31Pressemelding

Ncardia, an emerging drug discovery and development stem cell technology company whose mission is to deliver cardiac and neural solutions based on its best-in-class human induced pluripotent stem cell (iPSC)-derived technology, today announced the completion of a €10.5 million series B financing round. The round was led by Épimède, a Belgium venture capital firm. Ncardia is a privately-held company with operations in Europe and the US, that produces and commercializes high-quality, fully-functional human iPSC-derived cardiovascular and neuronal cell types. Using its cell products, Ncardia develops and commercializes assay services for drug safety and efficacy testing. Additionally the company has built up a strong portfolio of patents covering the use of stem cell models for these applications. Stefan Braam, CEO of Ncardia, commented: “At Ncardia, important progress h

Double Win for Vocalink at the 2017 Payments Awards17.11.2017 09:35Pressemelding

Vocalink, a Mastercard company, was last night awarded with two prestigious awards - The Overall Winner and the Payments Infrastructure of the Year Award, for its leading technology and expertise, and in recognition for a milestone year that saw Vocalink’s solutions transform the way people and businesses move money across the globe. 2017 saw Vocalink deliver ground-breaking immediate payments solutions both in the US and Thailand as well as enabling access to the UK payments industry through their payments gateway solution PayPort. The business also saw the launch of the new image based cheque clearing system, creating a robust and more efficient system in the UK. RTP ® in the US: This week, Vocalink announced the launch of RTP® (Real-Time Payments) in the US on behalf of The Clearing House; one of the most comprehensive real-tim

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom